Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808In the originally published online version of this article, reference 8 was missing from the list of references. The missing reference has now been added: "8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40."This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.
Authors
- Julie R. Brahmer (ORCID: https://orcid.org/0000-0002-2443-8395)
- Laura C. Cappelli (ORCID: https://orcid.org/0000-0003-2795-7059)
- Durrant Barasa
- Rebecca Fitzpatrick (ORCID: https://orcid.org/0000-0002-0913-8503)
- Clifton O. Bingham (ORCID: https://orcid.org/0000-0002-4752-5029)
- Elena Ghotbi
- Ami A. Shah
- Joseph Murray
- Shadpour Demehri
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-04-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0808.c1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00